Neurocrine Biosciences | NBIX - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 16.99B 1.99B 2026-06
Acadia Pharmaceuticals USD 307.96M 39.9M 2026-06
Agios Pharmaceuticals USD 44.74M 25.94M 2026-06
ALKERMES USD 496.01M 103.1M 2026-06
Alnylam Pharmaceuticals USD 1.29B 120M 2026-06
Amgen USD 10.1B 1.48B 2026-06
Biogen USD 2.74B 490M 2026-06
BioMarin Pharmaceutical USD 990M 224M 2026-06
Cytokinetics USD 28.6M 9.25M 2026-06
Enanta Pharmaceuticals USD 16.96M 50.68M 2024-12
Exelixis USD 628.69M 17.89M 2026-06
Gilead Sciences USD 7.8B 800M 2026-06
Halozyme Therapeutics USD 481M 104M 2026-06
Incyte USD 1.67B 400M 2026-06
Ionis Pharmaceuticals USD 268M 22M 2026-06
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 959M 148M 2026-06
Pfizer USD 15.03B 530M 2026-06
Prothena USD 51.08M 51.06M 2026-03
Regeneron Pharmaceuticals USD 4.29B 690M 2026-06
Repligen USD 204M 10M 2026-06
Rigel Pharmaceuticals USD 55.31M 18.47M 2024-09
Sarepta Therapeutics USD 401.3M 329.5M 2026-06
Teva Pharmaceutical Industries USD 12.67B 900M 2026-06
Ultragenyx Pharmaceutical USD 214M 78M 2026-06
Vertex Pharmaceuticals USD 3.33B 340M 2026-06